Rib-X Appoints Mark Leuchtenberger as President and CEO

Rib-X Appoints Mark Leuchtenberger as President and CEO
-- Susan Froshauer Appointed to New Role as Chief Scientific Officer --

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that Mark Leuchtenberger has been named President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Susan Froshauer, Ph.D., has been appointed to the newly created role of Chief Scientific Officer.

"I am excited to accept this opportunity to take Rib-X to the next stage of development as it becomes a commercially driven company"
"We are extremely pleased that Mark Leuchtenberger has joined Rib-X to lead our company into the next stage of our growth. Mark is a highly accomplished biotech executive with significant expertise in commercial operations and business development and is ideally suited to lead the company as the focus transitions to late stage product development and commercialization of our antibiotic product candidates," said George M. Milne Jr., Ph.D., Executive Chair of the Rib-X Board of Directors.

"I am excited to accept this opportunity to take Rib-X to the next stage of development as it becomes a commercially driven company," said Mark Leuchtenberger. "Rib-X has two late-stage antibiotic products with significant commercial potential including delafloxacin, an empirical first line antibiotic therapy with unique dual targeting structural features to provide greater potency, and radezolid, a best-in-class Gram-positive antibiotic that has the potential to offer expanded bacterial spectrum and improved utility to address unmet needs in the field ."

"Under Susan Froshauer‘s entrepreneurial leadership as CEO, the Rib-X team has developed an industry-leading pipeline of novel antibiotics which have been successfully advanced into late-stage development, and has transformed Rib-X's Nobel Prize winning technology into a powerful drug discovery engine, and in her new role as CSO, we will continue to rely on her unique abilities for leading-edge R&D for breakthrough antibiotics," continued Milne.

Mark Leuchtenberger comes to Rib-X Pharmaceuticals with significant experience in preparing biopharma companies to meet the challenges of product approval and commercialization. Prior to joining Rib-X, Mark Leuchtenberger served as President and CEO of Targanta Therapeutics Corporation and led the company's successful IPO in 2007 and acquisition in 2009. He joined Targanta from Therion Biologics Corporation, a privately held cancer vaccine company, where he served as President and CEO and led the company's lead product through development and commercial manufacturing build-up and raised over $120 million in private financing. Prior to Therion, Mr. Leuchtenberger was a senior officer at Biogen, where he served as Vice President, International and led all commercial operations outside of North America. Mr. Leuchtenberger received an M.B.A. from the Yale School of Management and a B.A. from Wake Forest University. He currently serves as Chairman of the MassBio Board of Directors and serves on the boards of Beth Israel Deaconess Medical Center and Wake Forest University.

About Rib-X

Rib-X Pharmaceuticals, Inc. has an industry-leading pipeline of novel antibiotics targeting multidrug-resistant infections in significant and growing segments of the $25 billion antibiotics market. The Rib-X product portfolio has four core programs including two late-stage product candidates, Delafloxacin and Radezolid, both potential best-in-class antibiotics being developed in market-preferred intravenous and oral formulations for maximum flexibility. The foundation of the Rib-X product portfolio is its proven discovery technology, the Ribosome Antibiotic Binding "RABTM" platform, using Nobel-prize-winning knowledge of ribosomal structure and mechanisms of antibiotic binding to create new chemical classes of antibiotics for a wide range of multidrug-resistant bacterial infections.

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.